Mirum Pharmaceuticals Stock Quote MIRM - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

39.47

Bid

39.48

Ask

39.65

Volume

129,007

38.81 Day's Range 39.70

23.14 52 Week Range 44.6995

Market Cap

1.86B

Previous Close

40.13

Open

39.01

Last Trade

39.56

Last Trade Time

12:49:23

Financial Volume

$ 5,063,150

VWAP

39.2471

Average Volume (3m)

796,637

Shares Outstanding

47,133,021

Dividend Yield

PE Ratio

-11.43

Earnings Per Share (EPS)

-3.47

Revenue

186.37M

Net Profit

-163.42M

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC... Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Headquarters

Dover, Delaware, USA

Founded

1970

Mirum Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MIRM. The last closing price for Mirum Pharmaceuticals was $40.13. Over the last year, Mirum Pharmaceuticals shares have traded in a share price range of $ 23.14 to $ 44.6995.

Mirum Pharmaceuticals currently has 47,133,021 shares outstanding. The market capitalization of Mirum Pharmaceuticals is $1.89 billion. Mirum Pharmaceuticals has a price to earnings ratio (PE ratio) of -11.43.

Dual Listed Biotech Begins to Prepare POC Preclinical Study for Diabetes & Obesity Dual Gene Therapy Program

Obesity and diabetes have become a problem for developed world countries. To address the global rise of these issues, this company is pursuing a dual-gene therapy strategy using proprietary To...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-1.53	-3.73170731707	41	44.6995	38.83	948148	42.13120631	CS
4	5.73	16.9828097214	33.74	44.6995	33.64	765384	39.55237197	CS
12	13.64	52.8068137824	25.83	44.6995	23.83	796637	32.92844894	CS
26	13.3	50.8215513947	26.17	44.6995	23.14	627796	30.27088022	CS
52	14.62	58.8329979879	24.85	44.6995	23.14	611472	29.88262409	CS
156	25.06	173.907009022	14.41	44.6995	12.82	415622	26.21716696	CS
260	25.86	190.007347539	13.61	44.6995	6.5126	304669	24.71486608	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
VSEEVSee Health Inc	$ 5.3731 (121.12%)	38.96M
XCURExicure Inc	$ 0.6684 (35.06%)	60.48M
DRMADermata Therapeutics Inc	$ 3.09 (24.60%)	34.78M
AKANAkanda Corporation	$ 1.76 (21.38%)	23.06M
TNDMTandem Diabetes Care Inc	$ 42.40 (20.42%)	2.77M
GPAKGamer Pakistan Inc	$ 0.0879 (-47.68%)	3.88M
LGMKLogicMark Inc	$ 0.2903 (-36.91%)	631.33k
XPONExpion360 Inc	$ 0.311 (-32.41%)	285.65k
HUBCWHub Cyber Security Ltd	$ 0.017 (-31.73%)	500
BIAFbioAffinity Technologies Inc	$ 1.6601 (-30.25%)	1.07M
NVDANVIDIA Corporation	$ 106.90 (-2.12%)	286.68M
SQQQProShares UltraPro Short QQQ	$ 9.8342 (6.66%)	196.06M
INTCIntel Corporation	$ 21.115 (-27.31%)	186.86M
AMZNAmazon.com Inc	$ 168.5966 (-8.41%)	84.1M
TQQQProShares UltraPro QQQ	$ 59.1599 (-6.63%)	70.22M